Lexicon Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$4.0Mgeneral payments (2019-2025)
$115Kresearch payments (2019-2025)
15,035clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Judith Swain | La Jolla, CA | Cardiovascular Disease | $150,534.96 |
| Robert Lefkowitz | Durham, NC | Cardiovascular Disease | $127,250.62 |
| Muthiah Vaduganathan | Boston, MA | Cardiovascular Disease | $92,503.52 |
| Michael Morse | Durham, NC | Hematology & Oncology | $89,963.80 |
| Krishnaswami Vijayaraghavan | Scottsdale, AZ | Cardiovascular Disease | $75,428.27 |
| Judith Swain | La Jolla, CA | $71,355.88 | |
| Steven Edelman | San Diego, CA | Internal Medicine | $67,889.48 |
| Stephen Greene | Durham, NC | Advanced Heart Failure and Transplant Cardiology | $61,595.83 |
| Joggy George | Houston, TX | Cardiovascular Disease | $58,761.08 |
| Henry Ward | New Haven, CT | Cardiovascular Disease | $57,371.48 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.